NCT06916767View on ClinicalTrials.gov

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Substudy B: CLL Patients

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Relapsed CLLRefractory CLLRefractory Lymphoma

Interventions

DRUG

BAFF CAR-T

Single infusion

DRUG

Obinutuzumab

IV administered

DRUG

Cyclophosphamide

500mg/m2 on days -5 to -3

DRUG

Fludarabine

30mg/m2 daily on days -5 to -3

Trial Locations (1)

44195

RECRUITING

Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland

All Listed Sponsors

collaborator

The Leukemia and Lymphoma Society

OTHER

lead

Paolo Caimi, MD

OTHER

NCT06916767 - Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Substudy B: CLL Patients | Biotech Hunter | Biotech Hunter